Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior histologic confirmation of non-small cell lung cancer (NSCLC).~* Optional: NSCLC histologic confirmation of metastasis of NSCLC.~* Presence of unidimensionally measurable disease in the brain.~* No previous or current malignancies at other sites with the exception of adequately treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin.~* Age: \>18 years.~* Subjects must not have systemic disease that in the opinion of the investigator is in immediate need of chemotherapy~* Karnofsky Performance status \>=70%.~* Absolute neutrophil count (ANC) \>1,500/mm\^3, platelets \>100,000/mm\^3, hemoglobin \>8 g/dL.~* Serum creatinine and bilirubin \<1.5 times upper normal limit of testing laboratory.~* Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) \<3 times upper limit of testing laboratory.~* Palliative radiation therapy to thorax and bone or other organs (except brain) is acceptable.~* Prior neurosurgery \>2 weeks from initiating treatment with temozolomide.~* Cortisone medication stable or decreasing within 2 weeks prior to initiating treatment with temozolomide.~* Patient is not pregnant or nursing and is advised and willing to use an effective method of contraception.~* Written informed consent.~Exclusion Criteria:~* Chemotherapy or biologic therapy within four weeks prior to initiating therapy with temozolomide.~* Prior radiation therapy for brain \<4 weeks from initiating therapy with temozolomide.~* Surgery within two weeks prior to temozolomide administration.~* Recursive Partitioning Analysis (RPA) class III~* Patients with a single brain metastasis amenable to radiosurgery of resection~* Known Human Immunodeficiency Virus (HIV) disease.~* Acute infection requiring intravenous antibiotics.~* Any reason making compliance to the protocol improbable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy with temozolomide and radiotherapy (Type: EXPERIMENTAL): None
- Radiotherapy alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).